These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
148 related items for PubMed ID: 3277733
1. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP). Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Kiss F. Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733 [Abstract] [Full Text] [Related]
2. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow. Prajda N, Kralovánszky J, Gal F, Kiss F, Kerpel-Fronius S. In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864 [Abstract] [Full Text] [Related]
3. Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone. Allan SG, Smyth JF. Br J Cancer; 1986 Mar; 53(3):355-60. PubMed ID: 3516192 [Abstract] [Full Text] [Related]
4. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C. Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808 [Abstract] [Full Text] [Related]
5. Preclinical toxicology of platinum analogues in dogs. Lelieveld P, van der Vijgh WJ, van Velzen D. Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1147-54. PubMed ID: 3308482 [Abstract] [Full Text] [Related]
6. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Dedon PC, Borch RF. Biochem Pharmacol; 1987 Jun 15; 36(12):1955-64. PubMed ID: 2954556 [Abstract] [Full Text] [Related]
7. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9). Schweitzer VG, Rarey KE, Dolan DF, Abrams GE, Sheridan C. Laryngoscope; 1986 Sep 15; 96(9 Pt 1):959-74. PubMed ID: 3528727 [Abstract] [Full Text] [Related]
8. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Lelieveld P, Van der Vijgh WJ, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, Danguy A. Eur J Cancer Clin Oncol; 1984 Aug 15; 20(8):1087-104. PubMed ID: 6381064 [Abstract] [Full Text] [Related]
9. The influence of platinum drugs on the radiation response of rat kidneys. van Rongen E, Kuijpers WC, Baten-Wittwer A. Radiother Oncol; 1994 May 15; 31(2):138-50. PubMed ID: 8066193 [Abstract] [Full Text] [Related]
10. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice. Endo K, Akamatsu K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K. Anticancer Res; 1992 May 15; 12(1):49-58. PubMed ID: 1567181 [Abstract] [Full Text] [Related]
11. [Acute and subacute toxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in laboratory rodents]. Härtl A, Güttner J, Horn U, Jelinek F, Stöckel U, Schröer HP, Hoffmann H. Arch Geschwulstforsch; 1989 May 15; 59(4):239-44. PubMed ID: 2640563 [Abstract] [Full Text] [Related]
12. Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats. Akamatsu K, Endo K, Matsumoto T, Morikawa K, Koizumi M, Koizumi K, Mitsui H. Jpn J Cancer Res; 1991 Jun 15; 82(6):724-31. PubMed ID: 1906857 [Abstract] [Full Text] [Related]
13. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC, Harrap KR. Cancer Chemother Pharmacol; 1994 Jun 15; 33(6):497-503. PubMed ID: 8137461 [Abstract] [Full Text] [Related]
14. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells. Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, Navarro-Ranninger C. J Med Chem; 2002 Apr 25; 45(9):1835-44. PubMed ID: 11960495 [Abstract] [Full Text] [Related]
15. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes]. Kimura S, Nakajima Y, Hasegawa S, Tazaki H. Nihon Hinyokika Gakkai Zasshi; 1989 Apr 25; 80(4):517-25. PubMed ID: 2664296 [Abstract] [Full Text] [Related]
16. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Harrap KR. Cancer Treat Rev; 1985 Sep 25; 12 Suppl A():21-33. PubMed ID: 3910219 [Abstract] [Full Text] [Related]
17. In vivo and in vitro effectivity of some platinum complexes. Balázová E, Hrubisko M, Ujházy V. Neoplasma; 1984 Sep 25; 31(6):641-7. PubMed ID: 6395026 [Abstract] [Full Text] [Related]
18. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study. Hannemann J, Baumann K. Arch Toxicol; 1990 Sep 25; 64(5):393-400. PubMed ID: 2169720 [Abstract] [Full Text] [Related]
19. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. Sharma H, Thatcher N, Baer J, Zaki A, Smith A, McAucliffe CA, Crowther D, Owens S, Fox BW. Cancer Chemother Pharmacol; 1983 Sep 25; 11(1):5-7. PubMed ID: 6349844 [Abstract] [Full Text] [Related]
20. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Cancer Res; 1984 Apr 25; 44(4):1693-7. PubMed ID: 6367971 [Abstract] [Full Text] [Related] Page: [Next] [New Search]